Tag Archive for: Alchemab Therapeutics

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference

Cambridge, UK, September 5, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that Young Kwon, PhD, Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2023 Healthcare Conference on 7 September 2023 at 4:30 p.m. ET. Read more…

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference

Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023. Read more…

Raising awareness of Rare Disease

Each year, Rare Disease Day aims to raise awareness of rare diseases and encourage positive change to patients’ lives. A disease is considered rare when it affects fewer than 1 in 2,000 people and there are 300 million people with rare diseases across the world.1 On Rare Disease Day 2023, we want to celebrate the […]

Alchemab Therapeutics | The Chain Podcast

THE CHAIN PODCAST Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent […]

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]